Determining the reliability of liver biopsies in NASH clinical studies
- PMID: 32887953
- DOI: 10.1038/s41575-020-00363-8
Determining the reliability of liver biopsies in NASH clinical studies
Comment on
-
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.J Hepatol. 2020 Dec;73(6):1322-1332. doi: 10.1016/j.jhep.2020.06.025. Epub 2020 Jun 28. J Hepatol. 2020. PMID: 32610115 Clinical Trial.
References
-
- Harrison, S. A. et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study. J. Hepatol. 72, 613–626 (2020). - DOI
-
- Davison, B. A. et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J. Hepatol. https://doi.org/10.1016/j.jhep.2020.06.025 (2020). - DOI - PubMed
-
- Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005). - DOI
-
- The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20, 15–20 (1994). - DOI
-
- Bedossa, P. et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56, 1751–1759 (2012). - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical